The United Kingdom and the United States have hammered out a landmark trade agreement that will guarantee no duties on UK drug exports being sold in the American market.
The Terms of the Deal
In exchange for the tariff guarantee, the UK has agreed to increase spending on medicines through the NHS. This commitment secures that import taxes on these vital exports will remain at zero for a timeframe of 36 months.
This development comes after earlier statements to significantly raise import taxes on patented drug imports, with increases discussed as high as double the cost.
"This deal between the United Kingdom strengthens the international landscape for new treatments and introduces much-needed equity to transatlantic drug exports," a release noted.
Commercial Importance
Pharmaceuticals are one of the the United Kingdom's largest export categories to the US, which is easily the largest destination for large British pharmaceutical firms.
Statistics show that in the year to the end of the third quarter, the UK shipped drugs worth £11.1bn to the US. This value accounted for 17.4% of total UK exports in that timeframe.
"This agreement secures work, boosts funding and facilitates the UK to emerge as a global hub for medical research," a government official stated.
Specific NHS Changes
The agreement involves several notable changes from the British government:
- Price Threshold Increase: The UK will lift the affordability limit at which it considers new therapies to be too expensive by twenty-five percent.
- Higher Drug Budget: There is a aim to increase total public funding on drugs from 0.3% of the national economy to 0.6% over the next decade.
- Rebate Cap: The percentage drug companies must return to the NHS to prevent overspending will be limited at 15%. Previously, refunds exceeded twenty percent.
Broader Context
The pact follows a ongoing dispute between the drug companies and the British authorities over spending levels and regulatory access.
This friction were heightened by arguments that American patients were charged a premium for the identical medicines than consumers in the other developed nations.
Over the last 18 months, several significant drug company projects in the UK have been paused or cancelled, while substantial funding commitments have been pledged toward US facilities.
The Science Minister stated that the NHS must spend more on drugs, noting that its spending on drugs had decreased as a percentage of its resources over the last ten years.
